AstraZeneca to invest $2B in Summit Therapeutics for cancer-drug tie-up; SMMT soars
What happened
AstraZeneca will invest $2 billion in Summit Therapeutics, announced late Monday September 28, and the two companies will collaborate on a series of clinical trials combining Summit's bispecific antibody ivonescimab with AstraZeneca's cancer treatments. AstraZeneca will buy newly issued preferred shares at an equivalent price of $18.36 per common share — an 18.6% premium to Summit's Monday close of $15.48 — giving it roughly a 12% stake (10.6% fully diluted), with closing expected within about a week. The first trials will pair ivonescimab with AstraZeneca's Claudin-18.2-targeting antibody-drug conjugate sonesitatug vedotin (Sone-Ve) in gastrointestinal cancers, each company retaining rights to its own molecule and sharing trial costs; a non-binding MOU points to a broader program combining ivonescimab with AstraZeneca's wider ADC portfolio.
Why it matters & what’s next are part of Pro, along with the audio summary.
Start your free 14-day trialWho’s affected & sources
Who’s affected
- Summit Therapeutics (SMMT) — up ~23% premarket to around $19; direct recipient of $2B cash infusion and a major pharma validation of ivonescimab.
- AstraZeneca (AZN) — UK shares up 1.6-1.7% to a two-month high; fills its bispecific oncology gap without an acquisition.
- Akeso (9926.HK) — Summit's licensor of ivonescimab; potential downstream interest as the drug gains Big Pharma validation.
- Peers with VEGF-bispecific programs (e.g. Bristol Myers Squibb BMY, Merck MRK) — incremental competition in next-gen immunotherapy.
- European pharma sector (GSK also +1.7%) — lifted the FTSE 100 by 0.34%.